Aiden Technology, an AI medical company, announced the completion of a CNY 200 million B+ funding round.
This round of funding was led by Haier Capital, followed by Xingtuo Capital, and old shareholders Sinovation Venture and Eastern Bell Capital continued to contribute.
This round of funding will be used for market expansion, talent acquisition, and brand development.
While DRG payment has already reached many countries, according to Lan Chen, vice president of Haier Capital Investment, it has only recently begun in China. I believe that the implementation of relevant policies will significantly improve coverage. Aiden's customer solutions, which employ AI and big data technology, have significantly improved customers' management capabilities and work efficiency, and are highly regarded by many customers. Mr. Zhu Wei led an excellent team, as evidenced by the company's rapid growth in recent years. We believed Aiden and his team could improve efficiency, empower patients, and add value to the healthcare industry.
Aiden Technology, founded in 2016, focuses on improving disease classification and case management processes, as well as the application of big data and artificial intelligence in the medical industry, and has since built a comprehensive DRG/DIP management system that spans multiple departments in the hospital. Nearly 4,000 secondary and tertiary medical institutions have used the company's big data services.